男性性腺機能低下症:パイプラインレビュー2019下半期

【英語タイトル】Male Hypogonadism - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120325)・商品コード:GDATA9120325
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:103
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Male Hypogonadism – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism – Pipeline Review, H2 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 3, 7, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism – Overview
Male Hypogonadism – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism – Companies Involved in Therapeutics Development
Allergan Plc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
TesoRx Pharma LLC
Viramal Ltd
Male Hypogonadism – Drug Profiles
chorionic gonadotropin ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPCN-1111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Block VDAC1 for Hypogonadism – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone propionate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism – Dormant Projects
Male Hypogonadism – Discontinued Products
Male Hypogonadism – Product Development Milestones
Featured News & Press Releases
Nov 01, 2019: Acerus provides update on temporary unavailability of NATESTO in Canada and South Korea
Oct 23, 2019: Acerus Pharma hosting key opinion leader meeting on unique clinical evidence of NATESTO for treatment of Hypogonadism
Oct 17, 2019: New data demonstrates that Natesto increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone through six months
Oct 16, 2019: Aytu BioScience to announce results from Natesto spermatogenesis study on Thursday, October 17
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Male Hypogonadism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Male Hypogonadism - Pipeline by Allergan Plc, H2 2019
Male Hypogonadism - Pipeline by Diurnal Group Plc, H2 2019
Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2019
Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2019
Male Hypogonadism - Pipeline by Lipocine Inc, H2 2019
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2019
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2019
Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2019
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2019
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2019
Male Hypogonadism - Pipeline by Viramal Ltd, H2 2019
Male Hypogonadism - Dormant Projects, H2 2019
Male Hypogonadism - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Male Hypogonadism, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products by Targets, H2 2019 16
Number of Products by Stage and Targets, H2 2019 16
Number of Products by Mechanism of Actions, H2 2019 18
Number of Products by Stage and Mechanism of Actions, H2 2019 18
Number of Products by Routes of Administration, H2 2019 20
Number of Products by Stage and Routes of Administration, H2 2019 20
Number of Products by Molecule Types, H2 2019 22
Number of Products by Stage and Molecule Types, H2 2019 22

【掲載企業】

Allergan Plc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
TesoRx Pharma LLC
Viramal Ltd

★調査レポート[男性性腺機能低下症:パイプラインレビュー2019下半期] (コード:GDATA9120325)販売に関する免責事項を必ずご確認ください。
★調査レポート[男性性腺機能低下症:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆